Abbott’s SonicForce coronary device meets safety, effectiveness goals in clinical trial
Bitget2026/11/01 20:45- Abbott’s investigational SonicForce coronary device met the TECTONIC trial’s primary safety and effectiveness endpoints, showing low treatment failure and high procedural success.
- Results were presented today at the Transcatheter Cardiovascular Therapeutics conference in San Diego and published in JACC: Cardiovascular Interventions.
- The device uses acoustic pressure waves to crack coronary calcium before stenting; potential approval would expand Abbott’s coronary device portfolio.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro gains against Canadian Dollar following German data
Morgan Stanley: Raised AbbVie’s target price to $346
Low base, high oil prices, and subsidies all drive growth: Tesla (TSLA.US) continues sales rebound in Northern Europe in October
In October of this year, registrations of new Tesla cars increased in several Nordic markets, continuing the recovery momentum of the American electric vehicle manufacturer's sales in the region.
Japan’s consumption is set for its first decline in over two years? The Bank of Japan preempts with a “precautionary statement”: Weak overall figures due to population shrinkage ≠ deteriorating demand, December rate hike may not be affected
The Bank of Japan stated that, due to the ongoing population decline, it is difficult for overall consumption in Japan to achieve strong growth. However, this also means that overall sluggish consumption does not necessarily indicate weakening household demand.
Crypto prices
More
